ID   U-178MG
AC   CVCL_A758
SY   U-178-MG; U-178 MG; U178-MG; U 178 MG; U178MG; MG 178; U-178; 178 MG; 178MG; 178 MG(5)
DR   BioGRID_ORCS_Cell_line; 692
DR   BioSample; SAMN10988405
DR   cancercelllines; CVCL_A758
DR   Cell_Model_Passport; SIDM01431
DR   Cosmic; 849851
DR   Cosmic; 849879
DR   Cosmic; 1610740
DR   Cosmic; 2516041
DR   DepMap; ACH-000208
DR   PharmacoDB; U178_1618_2019
DR   Progenetix; CVCL_A758
DR   Wikidata; Q54973519
RX   DOI=10.1007/0-306-46861-1_11;
RX   DOI=10.1007/978-1-4757-1647-4_7;
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=77569;
RX   PubMed=450131;
RX   PubMed=833871;
RX   PubMed=1847665;
RX   PubMed=2454731;
RX   PubMed=3518877;
RX   PubMed=4134536;
RX   PubMed=4139097;
RX   PubMed=4369403;
RX   PubMed=10416987;
RX   PubMed=10560660;
RX   PubMed=19435942;
RX   PubMed=22570425;
RX   PubMed=25984343;
RX   PubMed=27582061;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 45 hours (PubMed=25984343).
CC   HLA typing: A*01,02; B*07,12 (PubMed=77569).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (PubMed=10560660; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Heterozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Genome ancestry: African=2.94%; Native American=0%; East Asian, North=4.06%; East Asian, South=0%; South Asian=0%; European, North=69.5%; European, South=23.49% (PubMed=30894373).
ST   Source(s): PubMed=22570425; PubMed=27582061
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 10,11 (PubMed=27582061)
ST   D13S317: 11 (PubMed=22570425)
ST   D16S539: 10,13
ST   D18S51: 14,15
ST   D19S433: 14,15
ST   D21S11: 28,30
ST   D2S1338: 14,15
ST   D3S1358: 17
ST   D5S818: 12,13
ST   D7S820: 8,10 (PubMed=27582061)
ST   D7S820: 10 (PubMed=22570425)
ST   D8S1179: 13,14
ST   FGA: 22,26
ST   Penta D: 7,12
ST   Penta E: 7,12
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 18,19
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 25
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1007/978-1-4757-1647-4_7;
RA   Ponten J.;
RT   "Neoplastic human glia cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.175-206; Springer; New York (1975).
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=450131; DOI=10.1038/279797a0;
RA   Day R.S. III, Ziolkowski C.H.J.;
RT   "Human brain tumour cell strains with deficient host-cell reactivation
RT   of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.";
RL   Nature 279:797-799(1979).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1847665;
RA   Bongcam-Rudloff E., Nister M., Betsholtz C., Wang J.-L., Stenman G.,
RA   Huebner K., Croce C.M., Westermark B.;
RT   "Human glial fibrillary acidic protein: complementary DNA cloning,
RT   chromosome localization, and messenger RNA expression in human glioma
RT   cell lines of various phenotypes.";
RL   Cancer Res. 51:1553-1560(1991).
//
RX   PubMed=2454731;
RA   Nister M., Libermann T.A., Betsholtz C., Pettersson M.,
RA   Claesson-Welsh L., Heldin C.-H., Schlessinger J., Westermark B.;
RT   "Expression of messenger RNAs for platelet-derived growth factor and
RT   transforming growth factor-alpha and their receptors in human
RT   malignant glioma cell lines.";
RL   Cancer Res. 48:3910-3918(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4134536; DOI=10.1002/ijc.2910120215;
RA   Westermark B.;
RT   "The deficient density-dependent growth control of human malignant
RT   glioma cells and virus-transformed glia-like cells in culture.";
RL   Int. J. Cancer 12:438-451(1973).
//
RX   PubMed=4139097; DOI=10.1007/BF00295491;
RA   Mark J., Ponten J., Westermark B.;
RT   "G-band analyses of an established cell line of a human malignant
RT   glioma.";
RL   Humangenetik 22:323-326(1974).
//
RX   PubMed=4369403; DOI=10.1002/1097-0142(197408)34:2<274::AID-CNCR2820340209>3.0.CO;2-4;
RA   Wahlstrom T., Linder E., Saksela E., Westermark B.;
RT   "Tumor-specific membrane antigens in established cell lines from
RT   gliomas.";
RL   Cancer 34:274-279(1974).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=10560660; DOI=10.1097/00005072-199911000-00007;
RA   Schmidt E.E., Ichimura K., Goike H.M., Moshref A., Liu L.,
RA   Collins V.P.;
RT   "Mutational profile of the PTEN gene in primary human astrocytic
RT   tumors and cultivated xenografts.";
RL   J. Neuropathol. Exp. Neurol. 58:1170-1183(1999).
//
RX   PubMed=19435942; DOI=10.1215/15228517-2009-025;
RA   Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R.,
RA   Jones D.T.W., Collins V.P.;
RT   "IDH1 mutations are present in the majority of common adult gliomas
RT   but rare in primary glioblastomas.";
RL   Neuro-oncol. 11:341-347(2009).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27582061; DOI=10.1126/scitranslmed.aaf6853;
RA   Allen M., Bjerke M., Edlund H., Nelander S., Westermark B.;
RT   "Origin of the U87MG glioma cell line: good news and bad news.";
RL   Sci. Transl. Med. 8:354re3.1-354re3.4(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//